Immunotherapy has revolutionized the field of oncology, offering hope in the face of previously untreatable malignancies. This article aims to elucidate the principles of immunotherapy, its applications, and potential side effects.
Immunotherapy harnesses the power of the body's immune system to fight cancer. It works by either stimulating the immune system to attack cancer cells or providing it with synthetic immune system proteins. Key strategies include checkpoint inhibitors, CAR T-cell therapy, and cancer vaccines.
The scope of immunotherapy extends across various malignancies. It has proven effective in treating melanoma, lung, kidney, bladder, head and neck cancers, and certain types of lymphoma. Research is ongoing to expand its applicability to other cancer types.
Checkpoint inhibitors work by blocking immune checkpoints, proteins that prevent immune cells from attacking normal cells. By inhibiting these checkpoints, these drugs allow the immune system to recognize and attack cancer cells. Examples include pembrolizumab and nivolumab.
Chimeric Antigen Receptor (CAR) T-cell therapy involves modifying a patient's T cells to express receptors that bind to specific proteins on cancer cells, enhancing their ability to seek out and destroy the malignancy. This therapy has shown promising results in treating certain types of leukemia and lymphoma.
Cancer vaccines, like the HPV vaccine, aim to prevent cancer by stimulating the immune system to attack specific viruses that cause cancer. Therapeutic cancer vaccines, on the other hand, are designed to treat existing cancers by triggering the immune system to recognize and attack cancer cells.
While immunotherapy offers significant benefits, it also carries potential side effects, often resembling autoimmune reactions, as the immune system becomes more active. These can range from mild fatigue and fever to severe lung inflammation and endocrine disorders.
Immunotherapy represents a significant breakthrough in the treatment of many cancers. By understanding its principles, applications, and potential side effects, physicians can better guide their patients through the complexities of cancer treatment.
1.
High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy
2.
Papillary thyroid cancer: New markers offer hope for tailored treatment
3.
What Comes After Cancer?
4.
FDA Expands Durvalumab Label to Operable Lung Cancer
5.
In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.
1.
Finding Support: Connecting with the Vitiligo Community
2.
Essential Updates in Hematology in Daily Practice
3.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
4.
Living Better With Advanced Cancer Through Supportive Care
5.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
2.
Updates on Standard V/S High Risk Myeloma Treatment
3.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation